Jazz Pharmaceuticals Plc

Health Care
Biotechnology: Pharmaceutical Preparations
www.jazzpharmaceuticals.com

Earnings Score
Moat Score
Safety Score

Market Cap $6.81B
PE 12
Debt $6.22B
Cash $2.41B
EV $10.61B
FCF $1.36B

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	$560.12M
EBIT	$716.63M
ROE	14%
ROA	6%
FCF	$1.36B
Equity	$4.09B
Growth Stability	-155%
PE	12.15
PEG	1.31
PB	1.66
P/FCF	5.01
P/S	1.67
Price/Cash	0.35
Debt/Equity	1.52
Debt/FCF	4.58
Net Margins	14%
Op. Margins	18%
Earnings CAGR	-2%
Sales Growth YoY	8%
Sales Growth QoQ	3%
Sales CAGR	15%
FCF CAGR	10%
Equity CAGR	10%
Earnings Stability	0.02
Earnings Growth YoY	103%
Earnings Growth QoQ	-11%
Earnings CAGR 5Y	9%

Sales CAGR 5Y	15%
FCF CAGR 5Y	11%
Equity CAGR 5Y	3%
Earnings CAGR 3Y	6%
Sales CAGR 3Y	6%
FCF CAGR 3Y	11%
Equity CAGR 3Y	11%
Market Cap	$6.81B
Revenue	$4.07B
Dividend Yield	0%
Payout Ratio	0%
Assets	$12.01B
Total Debt	$6.22B
Cash	$2.41B
Shares Outstanding	60.63M
EV	10.61B
Earnings Score	6%
Moat Score	86%
Safety Score	52%
Final Score	48%
Working Capital	3.59B
Current Ratio	4.46
Shares Growth 3y	-1%
Equity Growth QoQ	-2%
Equity Growth YoY	10%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

SEC Filings

Direct access to Jazz Pharmaceuticals Plc (JAZZ) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Jazz Pharmaceuticals Plc compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Jazz Pharmaceuticals Plc compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR -2%

Stability 2%

loading chart...

Jazz Pharmaceuticals Plc Discounted Cash Flow

Fully customizable DCF calculator online for Jazz Pharmaceuticals Plc.

Years

Calculation mode

= $26B

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$1.4B	$1.5B	$1.6B	$1.8B	$2B	$2.1B	$2.3B	$2.6B	$2.8B	$3.1B	$3.4B	$34B
DCF		$1.4B	$1.3B	$1.3B	$1.3B	$1.3B	$1.3B	$1.3B	$1.3B	$1.3B	$1.3B	$13B
Value	$26B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Net Margins	25%	27%	30%	24%	24%	10%	-11%	-6%	11%	14%	14%
ROA	-	12%	10%	12%	10%	6%	1%	-1%	5%	6%	6%
ROE	-	21%	18%	16%	17%	7%	-8%	-7%	11%	14%	14%

Good Net Margins (13.77%)

Net Margins are high enough to offer a good protection on the profits in case of higher costs or higher interests. Furthermore higher margins reduce earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Debt over FCF	-	3.73	2.81	2.36	2.45	2.97	8.56	4.71	5.99	4.58	4.58
Debt over Equity	0.85	1.16	0.69	0.67	0.58	0.72	1.62	1.9	1.71	1.52	1.52
Growth Stability	-	-	-	100%	100%	49%	-82%	-155%	-	-	-155%

Bad Debt/FCF ratio (4.58)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Bad Debt/Equity ratio (1.52)

The company is overleveraged and has a bad balance between equity and debt.

Bad Graham’s Stability (-155%)

The company has a bad stability in its earnings, which is a sign of a bad competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	CAGR 5Y
Revenue YoY growth	-	12%	9%	17%	14%	9%	31%	18%	5%	6%	15%
Earnings YoY growth	-	20%	23%	-8%	17%	-54%	-238%	-32%	-285%	35%	9%
Equity YoY growth	-	17%	45%	2%	13%	18%	8%	-22%	21%	10%	3%
FCF YoY growth	-	17%	14%	17%	-5%	20%	-15%	66%	-14%	27%	11%